|Day Low/High||34.01 / 34.37|
|52 Wk Low/High||28.25 / 37.39|
The board of directors of Pfizer Inc. today declared a 30-cent fourth-quarter 2016 dividend on the company's common stock, payable December 1, 2016, to shareholders of record at the close of business on November 11, 2016.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.
Pfizer Inc. (NYSE:PFE) announced the confirmatory study (REFLECTIONS B537-02) evaluating the efficacy, safety, and immunogenicity of PF-06438179 (infliximab-Pfizer) compared to Remicade® (infliximab) met its primary...
Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.
Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that IBRANCE ® (palbociclib) be...
FDA announcements and a price increase should be beneficial to these portfolio names.
Two FDA panels have recommended that it's most serious warning label be removed from the Pfizer (PFE) drug Chantix.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc.
Today, a joint meeting of the U.S.
The $639 million deal marks the the third purchase for Brent Saunders since early August.
It is a matter of when, not if the market appreciates its potential.
For patient inventors, with more downside, Pfizer will reach a very low-risk entry zone.
Jefferies lowered its price target on Pfizer (PFE) to $39.
Drug companies like Merck, Pfizer and Johnson & Johnson are spending big bucks on the opposition of Proposition 61.
Today, Pfizer Inc announced it has launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression.
The most recent short interest data has been released for the 08/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
A strong performance from the ViiV Healthcare venture and a foreign-exchange booster make the case for the U.K.'s leading pharmaceuticals business.
The FDA released a report on Monday questioning Pfizer's (PFE) recent study of the psychiatric effects of its smoking cessation drug Chantix.
The drug company has several generic drugs that will compete with the likes of Pfizer's Viagra and Valeant's Acanya.
Zoetis is selling a lineup of drugs for dogs, and that looks to mean big business.
Zoetis is not averse to a little noise as investors, analysts take notice.
The Consumer Union is alleging that Mylan may have paid Teva to withhold its EpiPen competitor from the market.
If and when interest rates go up, this basket of stocks should continue to do well.